ArticleFrontiers in veterinary science2026
The boron uptake via LAT1 and survival analysis after boron neutron capture therapy in canine hemangiosarcoma cell lines.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Canine hemangiosarcoma (HSA) is a highly aggressive malignancy with limited effective therapies. Boron neutron capture therapy (BNCT) has begun to be recognized as a potential treatment in human angiosarcoma, but its applicability to canine HSA has not been explored. This study aimed to evaluate L-type amino acid transporter 1 (LAT1)-mediated uptake of boronophenylalanine (BPA), a Methods: Three canine HSA cell lines (JuB2, Ud6, Re21) were assessed for BPA uptake using fluorescence measurements, fluorescence imaging, and inductively coupled plasma-atomic emission spectrometry. LAT1 involvement was examined using the LAT1 inhibitor BCH. Clonogenic assays following X-ray or neutron irradiation, with or without BPA pretreatment, were performed to calculate survival fractions, dose-response curves, D10, relative biological effectiveness (RBE), and compound biological effectiveness (CBE). Results: All cell lines demonstrated BPA uptake, which was significantly reduced by BCH, confirming LAT1-mediated transport. Time-course analysis revealed cell line-dependent differences in intracellular Conclusion: These findings demonstrate functional LAT1-dependent BPA uptake and BNCT-induced cytotoxicity in canine HSA cells. The results provide foundational radiobiological evidence supporting the feasibility of BNCT in canine HSA and justify further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.